Coya Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.9M | $3.6M | $6.0M | $0 | — |
| Research and development | $16.7M | $11.9M | $5.5M | $4.4M | $2.5M |
| Operating expenses | $30.5M | $20.8M | $13.9M | $9.8M | $4.9M |
| Operating income | -$22.6M | -$17.2M | -$7.9M | -$9.8M | -$4.9M |
| Pretax income | -$21.2M | -$15.6M | -$7.3M | -$12.2M | — |
| Income tax expense | $3,089 | -$720,287 | $723,852 | $0 | — |
| Net income | -$21.2M | -$14.9M | -$8.0M | -$12.2M | -$4.9M |
| Balance Sheet | |||||
| Cash and equivalents | $46.8M | $38.3M | $32.6M | $5.9M | $4.3M |
| Current assets | $49.9M | $44.3M | $41.2M | $7.2M | $4.6M |
| Total assets | $50.0M | $44.3M | $41.3M | $8.4M | $4.8M |
| Current liabilities | $5.9M | $3.8M | $5.1M | $3.8M | $1.1M |
| Total liabilities | $6.9M | $4.8M | $5.6M | $16.8M | $1.1M |
| Stockholders' equity | $43.0M | $39.6M | $35.6M | -$8.4M | $3.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$10.7M | -$10.3M | -$11.2M | -$7.2M | -$3.9M |
| Depreciation and amortization | $27,361 | $27,361 | $27,361 | $27,361 | $16,133 |
| Stock-based compensation | $4.3M | $2.7M | $872,248 | $207,346 | $233,222 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 23.5M · Free float 70.4%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.